AbCellera Biologics (NASDAQ:ABCL) Given New $9.00 Price Target at Stifel Nicolaus

AbCellera Biologics (NASDAQ:ABCL) had its price target increased by investment analysts at Stifel Nicolaus from $8.00 to $9.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective points to a potential upside of 44.76% from the stock’s previous close.

Several other research firms have also recently weighed in on ABCL. Wall Street Zen cut shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of AbCellera Biologics in a research report on Friday, July 17th. JonesTrading initiated coverage on AbCellera Biologics in a report on Friday, April 10th. They issued a “buy” rating and a $11.00 target price on the stock. Cantor Fitzgerald boosted their target price on AbCellera Biologics from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Benchmark raised AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research note on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.40.

AbCellera Biologics Price Performance

Shares of NASDAQ:ABCL traded up $0.30 during trading on Thursday, hitting $6.22. 2,080,425 shares of the company’s stock were exchanged, compared to its average volume of 5,670,690. AbCellera Biologics has a 52-week low of $2.74 and a 52-week high of $8.44. The business’s 50-day simple moving average is $6.19 and its 200 day simple moving average is $4.66. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -12.95 and a beta of 1.20.

AbCellera Biologics (NASDAQ:ABCL) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.04). AbCellera Biologics had a negative return on equity of 14.86% and a negative net margin of 181.75%.The business had revenue of $4.05 million during the quarter, compared to the consensus estimate of $7.85 million. On average, sell-side analysts anticipate that AbCellera Biologics will post -0.67 EPS for the current fiscal year.

Institutional Trading of AbCellera Biologics

Institutional investors have recently modified their holdings of the company. Handelsbanken Fonder AB grew its position in shares of AbCellera Biologics by 27.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 147,900 shares of the company’s stock worth $1,161,000 after buying an additional 32,200 shares during the last quarter. Bank of America Corp DE boosted its position in shares of AbCellera Biologics by 13.9% in the 1st quarter. Bank of America Corp DE now owns 2,999,936 shares of the company’s stock worth $10,470,000 after purchasing an additional 367,064 shares in the last quarter. Royal Bank of Canada increased its position in AbCellera Biologics by 5.6% during the 1st quarter. Royal Bank of Canada now owns 394,753 shares of the company’s stock valued at $1,378,000 after buying an additional 20,897 shares in the last quarter. SEB Asset Management AB acquired a new stake in AbCellera Biologics in the first quarter worth about $1,188,000. Finally, Hsbc Holdings PLC raised its holdings in shares of AbCellera Biologics by 22.6% in the first quarter. Hsbc Holdings PLC now owns 143,472 shares of the company’s stock worth $499,000 after buying an additional 26,441 shares during the last quarter. 61.42% of the stock is currently owned by institutional investors.

AbCellera Biologics News Roundup

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on AbCellera from $11 to $12 and maintained an “overweight” rating. The new target implies substantial potential upside from the stock’s $5.92 reference price, signaling confidence in the company’s longer-term outlook. Benzinga analyst price-target update
• Positive Sentiment: AbCellera expects to report topline Phase II data for ABCL635 soon. The company also announced new T-cell engager collaborations that are expected to provide more than $110 million in upfront cash, improving near-term financial flexibility and potentially validating its antibody-discovery platform. AbCellera collaboration and ABCL635 update
• Neutral Sentiment: Investors are awaiting additional details from AbCellera’s Q2 earnings call regarding its collaboration pipeline, cash position and upcoming clinical milestones. Q2 2026 earnings call transcript
• Negative Sentiment: Q2 financial results missed expectations. AbCellera reported a loss of $0.18 per share versus the consensus estimate of a $0.14 loss, while revenue of $4.05 million fell well short of the $7.85 million forecast. The larger loss and sharply lower revenue highlight continued operating pressure and may limit gains until clinical and partnership catalysts deliver results. AbCellera Q2 2026 business results

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.